Kiniksa Pharmaceuticals International, plc 8-K

What Happened
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 8‑K on April 28, 2026 (Item 2.02) to announce its financial results for the quarter ended March 31, 2026. The company furnished a press release dated April 28, 2026 as Exhibit 99.1 summarizing those results.

Key Details

• Filing date: April 28, 2026; press release furnished as Exhibit 99.1.
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• The 8‑K itself references the press release for details; the report was signed by Douglas Barry, SVP, Chief Legal Officer and Secretary.

Why It Matters
This is a routine earnings disclosure that signals Kiniksa has released its quarterly results; investors should review the attached press release (Exhibit 99.1) for revenue, earnings, guidance, and other material metrics. The 8‑K does not include the numeric results in-line, so to assess financial impact or changes to outlook you should read the press release and any accompanying investor materials or subsequent 10‑Q filing.